Neff Thomas B 4
4 · FIBROGEN INC · Filed Aug 23, 2019
Insider Transaction Report
Form 4
FIBROGEN INCFGEN
Neff Thomas B
DirectorChief Executive Officer10% Owner
Transactions
- Exercise/Conversion
Common Stock
2019-08-22$2.90/sh+6,834$19,819→ 2,345,012 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-08-22−6,834→ 177,702 totalExercise: $2.90Exp: 2020-06-09→ Common Stock (6,834 underlying) - Exercise/Conversion
Common Stock
2019-08-21$2.90/sh+6,834$19,819→ 2,356,578 total - Sale
Common Stock
2019-08-21$44.79/sh−18,400$824,136→ 2,338,178 total - Sale
Common Stock
2019-08-21$44.81/sh−1,418$63,541→ 45,656 total(indirect: By Partnership) - Sale
Common Stock
2019-08-22$43.80/sh−17,100$748,980→ 2,327,912 total - Sale
Common Stock
2019-08-22$44.73/sh−1,300$58,149→ 2,326,612 total - Sale
Common Stock
2019-08-22$43.77/sh−1,418$62,066→ 44,238 total(indirect: By Partnership) - Exercise/Conversion
Stock Option (Right to Buy)
2019-08-21−6,834→ 184,536 totalExercise: $2.90Exp: 2020-06-09→ Common Stock (6,834 underlying)
Holdings
- 20,000(indirect: By Spouse)
Common Stock
- 60,946(indirect: See footnote)
Common Stock
Footnotes (8)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
- [F8]Fully vested.